Kezar Shifts Focus From Tumor Drug to Autoimmune Therapyby Lilu Anderson 14.08.2024Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
Adicet Bio Upgrade Sparks Investor Excitementby Terry Bingman 14.02.2024Adicet Bio receives an upgrade from Jones Trading, raising its rating to Buy with a new price target of $6.00. ...